Teva Pharmaceutical joint venture
Israeli firm has entered into an agreement with an unnamed "large multi-national corporation" for the establishment of a jointly owned company in the U.S. Teva said initial paid-up capital in the company of $10 mil. will be used as a vehicle for formation and/or acquisition of a marketing network for Teva's products in the U.S. "Teva has invested $1.5 mil. in the company and holds a 50% share"
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.